Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema

Alaa Dweikat,1 Arkan Jarrar,1 Mohammad Akkawi,2,3 Mohammad Shehadeh,2,3 Ammar Aghbar,3 Jamal Qaddumi,1 Maha Akkawi1 1Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine; 2Department of Special Surgeries, Faculty of Medicine and Health Scie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dweikat A, Jarrar A, Akkawi M, Shehadeh M, Aghbar A, Qaddumi J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	diabetic macular edema subfoveal choroidal thickness best-corrected visual acuity bevacizumab anti-vascular endothelial growth factor Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f018d1f5ff26404f8243382eadd3f40e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f018d1f5ff26404f8243382eadd3f40e
record_format	dspace
spelling	oai:doaj.org-article:f018d1f5ff26404f8243382eadd3f40e2021-12-02T19:21:58ZBaseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema1177-5483https://doaj.org/article/f018d1f5ff26404f8243382eadd3f40e2021-10-01T00:00:00Zhttps://www.dovepress.com/baseline-subfoveal-choroidal-thickness-as-a-predictor-for-response-to--peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Alaa Dweikat,1 Arkan Jarrar,1 Mohammad Akkawi,2,3 Mohammad Shehadeh,2,3 Ammar Aghbar,3 Jamal Qaddumi,1 Maha Akkawi1 1Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine; 2Department of Special Surgeries, Faculty of Medicine and Health Sciences, An-Najah National University Hospital, An-Najah National University, Nablus, Palestine; 3Ophthalmology Department, An-Najah National University Hospital, Nablus, PalestineCorrespondence: Mohammad Akkawi; Alaa Dweikat Email m.akkawi@najah.edu; alaadweikat43@gmail.comPurpose: This article aims to evaluate how the subfoveal choroidal thickness (SFCT) and best-corrected visual acuity (BCVA) respond to the intravitreal injection of bevacizumab and to assess the correlation between these changes. It will also assess the use of the baseline SFCT as a predictor for BCVA changes in eyes of treatment-naive, diabetic macular edema (DME) patients.Methods: This retrospective, consecutive case series comprised 59 eyes of 39 treatment-naive DME patients. Complete slit-lamp assessment, swept-source optical coherence tomography (SS-OCT) scans to measure SFCT and BCVA values were performed at two stages: baseline and one month after the third monthly injection of intravitreal bevacizumab.Results: Patients’ ages ranged from 46.3 to 76.4 years (mean: 62.6 ± 2.3). The mean SFCT was 318 ± 82 μm at baseline, which decreased after 3 months to 300 ± 66 μm (P-value = 0.021). There was an improvement in the mean of the logMAR best-corrected visual acuity (BCVA) from 0.7 (decimal equivalent: 0.2) to 0.5 (decimal equivalent: 0.3) (P-value = 0.019). There was no association between SFCT changes and BCVA changes (P-value = 0.180). Wilcoxon signed-rank test disclosed that a better BCVA improvement was related to a greater subfoveal choroidal thickness at baseline P-value < 0.00.Conclusion: Eyes with a higher baseline subfoveal choroidal thickness (SFCT) attained greater BCVA improvement than eyes with a lower baseline SFCT. In addition to this, changes to SFCT do not appear to correlate with BCVA changes. These findings do not support using OCT SFCT changes as a prognostic factor for changes to BCVA after intravitreal bevacizumab treatment in evaluating treatment-naive DME eyes.Keywords: diabetic macular edema, subfoveal choroidal thickness, best-corrected visual acuity, bevacizumab, anti-vascular endothelial growth factorDweikat AJarrar AAkkawi MShehadeh MAghbar AQaddumi JAkkawi MDove Medical Pressarticlediabetic macular edemasubfoveal choroidal thicknessbest-corrected visual acuitybevacizumabanti-vascular endothelial growth factorOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 4175-4180 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetic macular edema subfoveal choroidal thickness best-corrected visual acuity bevacizumab anti-vascular endothelial growth factor Ophthalmology RE1-994
spellingShingle	diabetic macular edema subfoveal choroidal thickness best-corrected visual acuity bevacizumab anti-vascular endothelial growth factor Ophthalmology RE1-994 Dweikat A Jarrar A Akkawi M Shehadeh M Aghbar A Qaddumi J Akkawi M Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
description	Alaa Dweikat,1 Arkan Jarrar,1 Mohammad Akkawi,2,3 Mohammad Shehadeh,2,3 Ammar Aghbar,3 Jamal Qaddumi,1 Maha Akkawi1 1Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine; 2Department of Special Surgeries, Faculty of Medicine and Health Sciences, An-Najah National University Hospital, An-Najah National University, Nablus, Palestine; 3Ophthalmology Department, An-Najah National University Hospital, Nablus, PalestineCorrespondence: Mohammad Akkawi; Alaa Dweikat Email m.akkawi@najah.edu; alaadweikat43@gmail.comPurpose: This article aims to evaluate how the subfoveal choroidal thickness (SFCT) and best-corrected visual acuity (BCVA) respond to the intravitreal injection of bevacizumab and to assess the correlation between these changes. It will also assess the use of the baseline SFCT as a predictor for BCVA changes in eyes of treatment-naive, diabetic macular edema (DME) patients.Methods: This retrospective, consecutive case series comprised 59 eyes of 39 treatment-naive DME patients. Complete slit-lamp assessment, swept-source optical coherence tomography (SS-OCT) scans to measure SFCT and BCVA values were performed at two stages: baseline and one month after the third monthly injection of intravitreal bevacizumab.Results: Patients’ ages ranged from 46.3 to 76.4 years (mean: 62.6 ± 2.3). The mean SFCT was 318 ± 82 μm at baseline, which decreased after 3 months to 300 ± 66 μm (P-value = 0.021). There was an improvement in the mean of the logMAR best-corrected visual acuity (BCVA) from 0.7 (decimal equivalent: 0.2) to 0.5 (decimal equivalent: 0.3) (P-value = 0.019). There was no association between SFCT changes and BCVA changes (P-value = 0.180). Wilcoxon signed-rank test disclosed that a better BCVA improvement was related to a greater subfoveal choroidal thickness at baseline P-value < 0.00.Conclusion: Eyes with a higher baseline subfoveal choroidal thickness (SFCT) attained greater BCVA improvement than eyes with a lower baseline SFCT. In addition to this, changes to SFCT do not appear to correlate with BCVA changes. These findings do not support using OCT SFCT changes as a prognostic factor for changes to BCVA after intravitreal bevacizumab treatment in evaluating treatment-naive DME eyes.Keywords: diabetic macular edema, subfoveal choroidal thickness, best-corrected visual acuity, bevacizumab, anti-vascular endothelial growth factor
format	article
author	Dweikat A Jarrar A Akkawi M Shehadeh M Aghbar A Qaddumi J Akkawi M
author_facet	Dweikat A Jarrar A Akkawi M Shehadeh M Aghbar A Qaddumi J Akkawi M
author_sort	Dweikat A
title	Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
title_short	Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
title_full	Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
title_fullStr	Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
title_full_unstemmed	Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
title_sort	baseline subfoveal choroidal thickness as a predictor for response to short-term intravitreal bevacizumab injections in diabetic macular edema
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/f018d1f5ff26404f8243382eadd3f40e
work_keys_str_mv	AT dweikata baselinesubfovealchoroidalthicknessasapredictorforresponsetoshorttermintravitrealbevacizumabinjectionsindiabeticmacularedema AT jarrara baselinesubfovealchoroidalthicknessasapredictorforresponsetoshorttermintravitrealbevacizumabinjectionsindiabeticmacularedema AT akkawim baselinesubfovealchoroidalthicknessasapredictorforresponsetoshorttermintravitrealbevacizumabinjectionsindiabeticmacularedema AT shehadehm baselinesubfovealchoroidalthicknessasapredictorforresponsetoshorttermintravitrealbevacizumabinjectionsindiabeticmacularedema AT aghbara baselinesubfovealchoroidalthicknessasapredictorforresponsetoshorttermintravitrealbevacizumabinjectionsindiabeticmacularedema AT qaddumij baselinesubfovealchoroidalthicknessasapredictorforresponsetoshorttermintravitrealbevacizumabinjectionsindiabeticmacularedema AT akkawim baselinesubfovealchoroidalthicknessasapredictorforresponsetoshorttermintravitrealbevacizumabinjectionsindiabeticmacularedema
_version_	1718376771723722752

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema

Ejemplares similares